Objective：This study aims to investigate the expression of CD163，CD68 in endometrial cancer（EC）and its relation with the clinicopathological features and overall survival rate. Methods：A total of 46 EC tumors were collected from January 2010 to December 2015 in Changzhou Maternal and Child Health Care hospital affiliated to Nanjing Medical University as the experimental group，while contemporaneous 25 cases with benign endometrial diagnosed were selected as the control group. Immunhistochemistry was applied to detect the expressions of CD68 and CD163 in the two groups. Taking the median expression level of tumor-associated macrophage（TAM）as the cut-off value，experimental group was divided into high expression group and low expression group of CD68 or CD163. The median ratio of CD163/CD68 was also taken as the cut-off value for CD163/CD68 high ratio group and low ratio group. The relationship of their expressions and clinicopathological features and prognosis of endometrial cancer were analyzed. Results：The expression of CD163 and CD68 in EC was significantly higher than that in control group. The expression of CD163 was associated with high pathological grade，high FIGO stage，lymph node metastasis. The expression of CD68 was associated with myometrial invasion，high FIGO stage. The ratio of CD163/CD68 was associated with high pathological grade，high FIGO stage，lymph node metastasis. Survival analysis found that there was no sigfnificant statistical difference in 5 year overall survival rate between the patients with the expression of CD163， CD68 and the ratio of CD163/CD68. Only lymph node metastasis was related to survival. Conclusion：TAM may be involved in the development of uterine endometrial cancer. The expression of CD163 and CD68 may play an important role in the progression of EC.